Stryker (SYK) Stock Price
Stryker Price
Over the last 19 years Stryker grew revenue by 8.4% annually, reaching 25.12 B USD. Earnings per share have grown at 8.2% per year over the last 19 years. For Stryker, the net margin of 12.9% is up versus 11.7% a few years ago. At today's price the dividend yield works out to roughly 1.23%. The payout ratio is around 40% of earnings. The dividend has grown at 15.5% per year over the past 19 years. The consensus 12-month price target for Stryker is 380.00 USD, about 38.0% above where the stock trades today. Of 34 analysts, 27 rate the stock a buy — an overall Buy consensus.
Stryker stock price
Stryker business model & stock analysis
Frequently asked questions about Stryker
The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.
Stryker Corp is primarily active in the healthcare industry.
The main competitors of Stryker Corp in the market are Johnson & Johnson, Medtronic, Zimmer Biomet Holdings, and Boston Scientific.
Stryker Corp is a renowned American medical technology company established in 1941. With over 80 years of experience, Stryker has evolved into a global leader specializing in surgical equipment and orthopedic implants. The company's roots trace back to its founding by Dr. Homer Stryker, an innovative orthopedic surgeon who developed various medical devices. Today, Stryker Corp offers a wide range of products across multiple medical disciplines, including reconstructive devices, neurotechnology, spine systems, and more. The company's commitment to innovation, coupled with strategic acquisitions, has solidified its position as a trusted name in the medical industry.
Stryker Corp has achieved significant milestones throughout its history. A major accomplishment for the company was the development and introduction of the first-ever surgical navigation system, the Navigation System II. This technology revolutionized surgical procedures by providing real-time imaging and guidance to surgeons, improving precision and patient outcomes. Another notable milestone for Stryker Corp was the acquisition of Howmedica, a leading orthopedic company, in 1998. This strategic move further strengthened Stryker Corp's position in the medical technology industry, enhancing its product portfolio and global presence. Over the years, the company has continued to innovate and has been recognized for its advancements in medical devices and solutions.
Stryker Corp is primarily present in various countries and regions worldwide. Some of the key locations include the United States, where the company is headquartered in Kalamazoo, Michigan. Additionally, Stryker has a significant presence in Europe, with operations in countries such as Germany, France, the United Kingdom, Italy, and Switzerland. The company is also active in the Asia-Pacific region, specifically in countries like China, Japan, India, and Australia. With its global reach, Stryker Corp ensures its innovative medical technologies and products are available to healthcare professionals and patients across different parts of the world.
Stryker Corp represents values of innovation, integrity, and excellence in the medical technology industry. The company's corporate philosophy centers around delivering high-quality products and services that improve patient outcomes and enhance healthcare providers' capabilities. By continually investing in research and development, Stryker strives to introduce cutting-edge solutions that address critical healthcare needs and promote sustainable growth. With a commitment to ethical business practices and global collaboration, Stryker focuses on delivering value to its stakeholders, including healthcare professionals, patients, employees, and shareholders. Stryker Corp's dedication to advancing medical technology and improving lives embodies its core values and corporate philosophy.
Analysts currently set an average price target of 382.61 USD for the Stryker stock (median: 380.00 USD), implying +38.9 % versus the latest price. The consensus is based on 34 analyst ratings.
34 analysts currently rate the Stryker stock: 27 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Stryker to generate revenue of 27.23 B USD and earnings per share of 14.99 USD.
Converted at the current exchange rate, the Stryker share trades at 245.92 EUR (275.40 USD).
The Stryker share (SYK) is listed on 12 stock exchanges, including: NYSE (SYK), London (0R2S.L), SIX (Zürich) (SYK.SW), XETRA (SYK.DE), Frankfurt (SYK.F), München (SYK.MU), Stuttgart (SYK.SG), Düsseldorf (SYK.DU).
Stryker Corp is a US-American company that specializes in the manufacturing and sale of medical devices, implantable products, and medical services. The company was founded in 1941 and has since become a leading company in the medical technology industry. Stryker has four business segments, namely Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. In the Medical Devices segment, Stryker offers a wide range of products including endoscopy devices, respiratory devices, patient monitoring devices, neurological monitoring devices, and medical lighting systems. These products are used in hospitals and clinical facilities for patient diagnosis and treatment. In Orthopedics, Stryker is one of the world leaders in implants and instruments for joint surgery. The company offers products for the hip, knee, shoulder, wrist, and other joints. Stryker has also taken a leading role in introducing robotics in surgery in this field. The Mako robot allows for precise implantations, enabling patients to have faster recovery and improved quality of life. The Medical and Surgical Instruments segment includes a wide range of instruments for surgery, including surgical saws, scalpels, forceps, and other instruments for various surgical procedures. These instruments are used by physicians for a variety of surgical interventions. In the Neurotechnology and Spine Products segment, Stryker develops and distributes products for spinal surgery, including implants for intervertebral discs and for stabilization of the cervical and lumbar spine. In addition to selling products, Stryker also offers medical services. This includes consulting and support for the implementation of products and systems in hospitals and medical facilities. Technical support and customer service are also part of the offerings. Stryker's business model is based on its ability to develop and produce innovative and high-quality products for the medical field. The company emphasizes close collaboration with medical professionals to ensure that the offered products meet the requirements of the practice and enable optimal treatment for patients. The company also strives to continuously improve its products and develop new technologies. In particular, the introduction of robotics in surgery offers Stryker significant growth opportunities as it has the potential for higher efficiency, precision, and better treatment outcomes. Overall, Stryker is a leading company in the medical technology industry, specializing in the development of innovative products and the provision of high-quality medical services. The company has a wide range of products in various business segments, including Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. Stryker's business model is based on serving medical professionals with high-quality products and services and developing innovative technologies to achieve even better treatment outcomes for patients.
The expected revenue of Stryker is 27.23 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Stryker is 5.79 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Stryker is currently 18.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stryker stock.
The price-to-sales ratio (P/S) of Stryker is currently 3.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stryker stock.
The Eulerpool Quality Score for Stryker is 8/10.
The ISIN of Stryker is US8636671013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stryker is 864952. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stryker is SYK. The ticker symbol is used to trade Stryker shares on the stock exchange.
Stryker stock
Stryker Peer Group
Stryker Ticker
Stryker FIGI
All fundamentals and in-depth analysis of Stryker
Our stock analysis for Stryker stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stryker. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.